Bicocca Open Archive

Logo unimib boa

Mologni, L., Piazza, R., Khandelwal, P., Pirola, A., Gambacorti-Passerini, C. (2017). Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients. AMERICAN JOURNAL OF HEMATOLOGY, 92(10), E623-E625 [10.1002/ajh.24865].

Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients

Mologni, L
Co-primo
;Piazza, R
Co-primo
;Khandelwal, P;Gambacorti-Passerini, C
Ultimo
2017
Articolo in rivista - Articolo scientifico
Disease-Free Survival; Female; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Survival Rate; Exome; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Hematology
English
2017
E623
E625
3
WOS:000409203200019
2-s2.0-85027534317
28718956
Mologni, L., Piazza, R., Khandelwal, P., Pirola, A., Gambacorti-Passerini, C. (2017). Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients. AMERICAN JOURNAL OF HEMATOLOGY, 92(10), E623-E625 [10.1002/ajh.24865].
01 - Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/183223
Citazioni
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
Social impact